228 related articles for article (PubMed ID: 34399812)
21. Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study.
Call JA; Prendergast BM; Jensen LG; Ord CB; Goodman KA; Jacob R; Mell LK; Thomas CR; Jabbour SK; Miller RC
Am J Clin Oncol; 2016 Feb; 39(1):8-12. PubMed ID: 24401669
[TBL] [Abstract][Full Text] [Related]
22. Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival.
Weber HE; Dröge LH; Hennies S; Herrmann MK; Gaedcke J; Wolff HA
Strahlenther Onkol; 2015 Nov; 191(11):827-34. PubMed ID: 26050046
[TBL] [Abstract][Full Text] [Related]
23. Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer.
Joseph K; Nijjar Y; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Ghosh S; Syme A; Nijjar T; Mulder K; Doll C; Wong C; Field C
Radiother Oncol; 2015 Nov; 117(2):234-9. PubMed ID: 26306677
[TBL] [Abstract][Full Text] [Related]
24. Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005).
Gul SK; Tepetam H; Yildiz F; Er I; Oksuz DC; Parvizi M; Ozden AS; Alicikus ZA; Sari SY; Alomari O; Gorken IB
Clin Colorectal Cancer; 2023 Sep; 22(3):318-326. PubMed ID: 37336706
[TBL] [Abstract][Full Text] [Related]
25. Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation.
Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Trino E; Cassoni P; Arena V; Baccega M; Racca P; Faletti R; Rondi N; Morino M; Ricardi U
Cancer Invest; 2018; 36(5):279-288. PubMed ID: 29953269
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.
Koerber SA; Slynko A; Haefner MF; Krug D; Schoneweg C; Kessel K; Kopp-Schneider A; Herfarth K; Debus J; Sterzing F
Radiat Oncol; 2014 May; 9():113. PubMed ID: 24886574
[TBL] [Abstract][Full Text] [Related]
27. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
[TBL] [Abstract][Full Text] [Related]
28. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
29. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
30. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
[TBL] [Abstract][Full Text] [Related]
32. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
[TBL] [Abstract][Full Text] [Related]
33. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Lukovic J; Hosni A; Liu A; Chen J; Tadic T; Patel T; Li K; Han K; Lindsay P; Craig T; Brierley J; Barry A; Wong R; Ringash J; Dawson LA; Kim JJ
Radiother Oncol; 2023 Jan; 178():109429. PubMed ID: 36455685
[TBL] [Abstract][Full Text] [Related]
35. Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients.
Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Munoz F; Rondi N; Morino M; Racca P; Ricardi U
Br J Radiol; 2016; 89(1060):20150832. PubMed ID: 26838953
[TBL] [Abstract][Full Text] [Related]
36. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
Mohammadkhani Shali S; Schmitt V; Behrendt FF; Winz OH; Heinzel A; Mottaghy FM; Eble MJ; Verburg FA
Eur J Radiol; 2016 Aug; 85(8):1390-4. PubMed ID: 27423677
[TBL] [Abstract][Full Text] [Related]
37. Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Anticancer Res; 2016 Apr; 36(4):1943-8. PubMed ID: 27069184
[TBL] [Abstract][Full Text] [Related]
38. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
[TBL] [Abstract][Full Text] [Related]
39. Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
Ludmir EB; Kachnic LA; Czito BG
Surg Oncol Clin N Am; 2017 Jan; 26(1):91-113. PubMed ID: 27889040
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
De Bari B; Jumeau R; Bouchaab H; Vallet V; Matzinger O; Troussier I; Mirimanoff RO; Wagner AD; Hanhloser D; Bourhis J; Ozsahin EM
Acta Oncol; 2016 Jun; 55(6):767-73. PubMed ID: 27034083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
